Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Tax Provisions (2020 - 2026)

Cytek Biosciences filings provide 6 years of Tax Provisions readings, the most recent being $40.0 million for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 5461.81% to $40.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.6 million, a 9442.97% increase, with the full-year FY2025 number at $36.7 million, up 11368.12% from a year prior.
  • Tax Provisions hit $40.0 million in Q4 2025 for Cytek Biosciences, up from -$2.3 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $40.0 million in Q4 2025 to a low of -$2.8 million in Q1 2024.
  • Median Tax Provisions over the past 5 years was $75000.0 (2021), compared with a mean of $1.8 million.
  • Biggest five-year swings in Tax Provisions: crashed 2390.0% in 2022 and later soared 5461.81% in 2025.
  • Cytek Biosciences' Tax Provisions stood at $1.6 million in 2021, then plummeted by 75.39% to $396000.0 in 2022, then crashed by 451.52% to -$1.4 million in 2023, then surged by 151.72% to $720000.0 in 2024, then soared by 5461.81% to $40.0 million in 2025.
  • The last three reported values for Tax Provisions were $40.0 million (Q4 2025), -$2.3 million (Q3 2025), and -$1.2 million (Q2 2025) per Business Quant data.